Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.59 |
| ▸ | CHKA known ✓ | P35790 | 8/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | CHRNA10 | Q9GZZ6 | 3/20 | 0.47 |
| ▸ | CHRNA9 | Q9UGM1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307716 | 0.85 | ALDH1A1 (0.53) | ACHEBCHECHKACHRNA7CHRNA10 | |
| Bromide SCHEMBL26091565 | 0.84 | CHRNA7 (0.58) | ACHEBCHECHKACHRNA7CHRNA10 | |
| Hydrochloric Acid SCHEMBL7307884 | 0.83 | ALDH1A1 (0.56) | ACHEBCHECHKACHRNA7CHRNA10 | |
| SCHEMBL4404627 | 0.77 | CHRNA7 (0.71) | ACHEBCHECHRNA7CHRNA10CHRNA9 | |
| SCHEMBL4402996 | 0.77 | CHRNA7 (0.66) | ACHEBCHECHKACHRNA7CHRNA10 | |
| SCHEMBL4400676 | 0.75 | CHRNA7 (0.62) | CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL21202131 | 0.74 | ACHE (0.47) | ACHEBCHECHKA | |
| Bromide SCHEMBL23858158 | 0.71 | CHKA (0.49) | ACHEBCHECHKA | |
| Bromide SCHEMBL15821503 | 0.71 | ACHE (0.50) | ACHEBCHECHKA | |
| Bromide SCHEMBL26093360 | 0.70 | CHRNA7 (0.70) | ACHEBCHECHRNA7CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419206-B1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (ES) | 2025-09-17 | — | — | EP | disclosed |
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2024-12-19 | — | — | US | disclosed |
| EP-4419206-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundacio Institut de Bioenginyeria de Catalunya (ES) | 2024-08-28 | — | — | EP | disclosed |
| CN-118475559-A | Compounds for malaria treatment | 加泰罗尼亚生物工程基金会研究所 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023067170-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | ABAT, GLS2, CPS1 | ACHE 148/4885CHKA 698/4885BCHE 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.